Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.
Reumatol Clin (Engl Ed)
; 17(10): 559-561, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1537018
ABSTRACT
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Interleukin 1 Receptor Antagonist Protein
/
Antibodies, Monoclonal, Humanized
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Prognostic study
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Reumatol Clin (Engl Ed)
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS